Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on Preprints.org…
Categories: Partner
Posts regarding work and activities with partners
SCT Announces Partnership with Antibody Solutions at 2017 Antibody Engineering & Therapeutics Conference
Sunnyvale, Calif. (Dec. 4, 2017) – Antibody Solutions, a leader in discovery of therapeutic, biomarker and critical reagent antibodies, and Single Cell Technology, Inc. (SCT), a pioneer in single cell analysis technology, have launched a partnership…
Single Cell Technology and AB Biosciences announce collaboration
Single Cell Technology, Inc. (SCT) and AB Biosciences (ABB) today announced a collaboration to identify therapeutic antibodies. SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the…